Drug Detail:Ado-trastuzumab emtansine (Ado-trastuzumab emtansine [ ay-doe-tras-tooz-ue-mab-em-tan-seen ])
Drug Class: HER2 inhibitors
Ado-Trastuzumab Emtansine Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of ado-trastuzumab during breastfeeding. Because trastuzumab is a large protein molecule with a molecular weight of 145,531 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. However, ado-trastuzumab emtansine also contains DM1 which is a small-molecule toxin that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends avoiding breastfeeding during and for 7 months following ado-trastuzumab emtansine therapy.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
-
Koenig A, de Albuquerque Diniz EM, Barbosa SF, et al. Immunologic factors in human milk: The effects of gestational age and pasteurization. J Hum Lact. 2005;21:439–43. PMID. [PubMed: 16280560]
- 2.
-
Adhisivam B, Vishnu Bhat B, Rao K, et al. Effect of Holder pasteurization on macronutrients and immunoglobulin profile of pooled donor human milk. J Matern Fetal Neonatal Med. 2019;32:3016–9. PMID. [PubMed: 29587541]
- 3.
-
Rodríguez-Camejo C, Puyol A, Fazio L, et al. Antibody profile of colostrum and the effect of processing in human milk banks: Implications in immunoregulatory properties. J Hum Lact. 2018;34:137–47. PMID. [PubMed: 28586632]
Substance Identification
Substance Name
Ado-Trastuzumab Emtansine
CAS Registry Number
1018448-65-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Antineoplastic Agents
Ado-Trastuzumab Emtansine
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification